Fate Therapeutics Inc $ 48.19 0.67 (1.41%)
Volume:
1,349,519
Avg Vol (1m):
974,125
Market Cap $:
4.19 Bil
Enterprise Value $:
3.73 Bil
P/E (TTM):
0.00
P/B:
8.84
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.58 | ||
| Equity-to-Asset | 0.73 | ||
| Debt-to-Equity | 0.17 | ||
| Debt-to-EBITDA | -0.71 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 13.19 | ||
| Beneish M-Score | -0.83 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -903.76 | ||
| Net Margin % | -881.86 | ||
| ROE % | -43.68 | ||
| ROA % | -32.04 | ||
| ROC (Joel Greenblatt) % | -219.86 | ||
| 3-Year Revenue Growth Rate | 4.1 | ||
| 3-Year EBITDA Growth Rate | -12.3 | ||
| 3-Year EPS without NRI Growth Rate | -11.1 |
FATE
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 8.84 | ||
| PS Ratio | 275.38 | ||
| EV-to-EBIT | -32.02 | ||
| EV-to-EBITDA | -32.77 | ||
| EV-to-Revenue | 282.56 | ||
| Current Ratio | 11.92 | ||
| Quick Ratio | 11.92 | ||
| Days Sales Outstanding | 47.44 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.83 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 141.74 | ||
| Earnings Yield (Greenblatt) % | -3.14 |